
## Angela Stefanachi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6907904/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds. Molecules, 2018, 23, 250.	3.8	388
2	Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. Bioorganic and Medicinal Chemistry, 2013, 21, 146-152.	3.0	80
3	Design, Synthesis, and Biological Evaluation of Imidazolyl Derivatives of 4,7-Disubstituted Coumarins as Aromatase Inhibitors Selective over 17-α-Hydroxylase/C17â^'20 Lyase. Journal of Medicinal Chemistry, 2011, 54, 1613-1625.	6.4	78
4	Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 7450-7456.	3.0	60
5	Design, Synthesis, and Biological Evaluation of Coumarin Derivatives Tethered to an Edrophoniumâ€like Fragment as Highly Potent and Selective Dual Binding Site Acetylcholinesterase Inhibitors. ChemMedChem, 2010, 5, 1616-1630.	3.2	58
6	Discovery, Biological Evaluation, and Structure–Activity and â^'Selectivity Relationships of 6′-Substituted ( <i>E</i> )-2-(Benzofuran-3(2 <i>H</i> )-ylidene)- <i>N</i> -methylacetamides, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 2651-2664.	6.4	56
7	Solid-Phase Synthesis and Insights into Structureâ^'Activity Relationships of Safinamide Analogues as Potent and Selective Inhibitors of Type B Monoamine Oxidase. Journal of Medicinal Chemistry, 2007, 50, 4909-4916.	6.4	49
8	Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9. European Journal of Medicinal Chemistry, 2012, 58, 368-376.	5.5	42
9	Fine molecular tuning at position 4 of 2H-chromen-2-one derivatives in the search of potent and selective monoamine oxidase B inhibitors. European Journal of Medicinal Chemistry, 2013, 70, 723-739.	5.5	41
10	Design, Synthesis, and Structureâ^'Activity Relationships of 1-,3-,8-, and 9-Substituted-9-deazaxanthines at the Human A2BAdenosine Receptor. Journal of Medicinal Chemistry, 2006, 49, 282-299.	6.4	37
11	Potent Galloyl-Based Selective Modulators Targeting Multidrug Resistance Associated Protein 1 and P-glycoprotein. Journal of Medicinal Chemistry, 2012, 55, 424-436.	6.4	34
12	Human ether-Ã-go-go-related potassium channel: exploring SAR to improve drug design. Drug Discovery Today, 2020, 25, 344-366.	6.4	33
13	Strategies of multi-objective optimization in drug discovery and development. Expert Opinion on Drug Discovery, 2011, 6, 871-884.	5.0	31
14	Computational methods for the design of potent aromatase inhibitors. Expert Opinion on Drug Discovery, 2013, 8, 395-409.	5.0	28
15	1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor. Bioorganic and Medicinal Chemistry, 2008, 16, 2852-2869.	3.0	27
16	Design, synthesis, and biological evaluation of glycine-based molecular tongs as inhibitors of Aβ1–40 aggregation in vitro. Bioorganic and Medicinal Chemistry, 2008, 16, 4810-4822.	3.0	27
17	8-Substituted-9-deazaxanthines as adenosine receptor ligands: design, synthesis and structure-affinity relationships at A2B. European Journal of Medicinal Chemistry, 2004, 39, 879-887.	5.5	26
18	Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration. Journal of Medicinal Chemistry, 2020, 63, 14448-14469.	6.4	26

ANGELA STEFANACHI

#	Article	IF	CITATIONS
19	Mind the Gap! A Journey towards Computational Toxicology. Molecular Informatics, 2016, 35, 294-308.	2.5	25
20	1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: Design, synthesis, structure–affinity and structure–selectivity relationships. Bioorganic and Medicinal Chemistry, 2008, 16, 9780-9789.	3.0	24
21	Fast and highly efficient one-pot synthesis of 9-deazaxanthines. Tetrahedron Letters, 2003, 44, 2121-2123.	1.4	23
22	Trimethoxybenzanilide-Based P-Glycoprotein Modulators: An Interesting Case of Lipophilicity Tuning by Intramolecular Hydrogen Bonding. Journal of Medicinal Chemistry, 2014, 57, 6403-6418.	6.4	23
23	Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4′-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase. European Journal of Medicinal Chemistry, 2015, 89, 106-114.	5.5	22
24	Enhancing the Sensitivity of Biotinylated Surfaces by Tailoring the Design of the Mixed Self-Assembled Monolayer Synthesis. ACS Omega, 2020, 5, 16762-16771.	3.5	22
25	Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML. International Journal of Molecular Sciences, 2020, 21, 4469.	4.1	19
26	3,4-Dihydropyrimidin-2(1 <i>H</i> )-ones as Antagonists of the Human A <sub>2B</sub> Adenosine Receptor: Optimization, Structure–Activity Relationship Studies, and Enantiospecific Recognition. Journal of Medicinal Chemistry, 2021, 64, 458-480.	6.4	19
27	Solid phase synthesis of a molecular library of pyrimidines, pyrazoles, and isoxazoles with biological potential. Tetrahedron Letters, 2010, 51, 1702-1705.	1.4	18
28	Design, Synthesis, and Biological Evaluation of 2â€Aminobenzanilide Derivatives as Potent and Selective HDAC Inhibitors. ChemMedChem, 2012, 7, 1256-1266.	3.2	16
29	Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R). European Journal of Medicinal Chemistry, 2020, 188, 112037.	5.5	14
30	Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to. Molecules, 2020, 25, 4210.	3.8	13
31	1,3-Dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure–affinity and structure–selectivity relationships. Bioorganic and Medicinal Chemistry, 2009, 17, 3618-3629.	3.0	12
32	Insights into the Complex Formed by Matrix Metalloproteinase-2 and Alloxan Inhibitors: Molecular Dynamics Simulations and Free Energy Calculations. PLoS ONE, 2011, 6, e25597.	2.5	12
33	Synthesis of 1-Substituted-6-methyluracils. Chemical and Pharmaceutical Bulletin, 2003, 51, 1025-1028.	1.3	9
34	Discovery of a Potent and Selective Heteroâ€Bivalent AChE Inhibitor via Bioisosteric Replacement. Molecular Informatics, 2011, 30, 133-136.	2.5	8
35	Toward a fragment-based approach to MMPs inhibitors: an expedite and efficient synthesis of N-hydroxylactams. Tetrahedron Letters, 2012, 53, 4114-4116.	1.4	8
36	Surface composition of mixed self-assembled monolayers on Au by infrared attenuated total reflection spectroscopy. Applied Surface Science, 2021, 559, 149883.	6.1	7

Angela Stefanachi

#	Article	IF	CITATIONS
37	Investigating Structural Requirements for the Antiproliferative Activity of Biphenyl Nicotinamides. ChemMedChem, 2017, 12, 1380-1389.	3.2	6
38	Negatively charged ions to probe self-assembled monolayer reorganization driven by interchain interactions. Journal of Materials Chemistry C, 2021, 9, 10935-10943.	5.5	5
39	Galloyl benzamide-based compounds modulating tumour necrosis factor α-stimulated c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signalling pathways. Journal of Pharmacy and Pharmacology, 2015, 67, 1380-1392.	2.4	4
40	Hydroxy-Propil-β-Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic Cancer Cell Models. International Journal of Molecular Sciences, 2020, 21, 6545.	4.1	4
41	Synthetic Applications of Polystyrene-Supported 1,1,3,3-Tetramethylguanidine. Combinatorial Chemistry and High Throughput Screening, 2008, 11, 843-847.	1.1	3
42	Design, synthesis, biological evaluation, <scp>NMR</scp> and <scp>DFT</scp> studies of structurally simplified trimethoxy benzamides as selective Pâ€glycoprotein inhibitors: the role of molecular flatness. Chemical Biology and Drug Design, 2016, 88, 820-831.	3.2	3
43	Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1 Antagonists. Journal of Medicinal Chemistry, 2022, 65, 2091-2106.	6.4	2
44	Fast and Highly Efficient One-Pot Synthesis of 9-Deazaxanthines ChemInform, 2003, 34, no.	0.0	0
45	8-Substituted-9-deazaxanthines as Adenosine Receptor Ligands: Design, Synthesis and Structure-Affinity Relationships at A2B ChemInform, 2005, 36, no.	0.0	0